Opthea sees final patient for Phase 2b eye disease trial

Company News

by Rachael Jones

Biopharmaceutical company Opthea (ASX:OPT) for eye disease has seen the final patient in the Company’s Phase 2b trial of OPT-302 for wet age-related macular degeneration (AMD) has completed their last clinical visit.

This important milestone paves the way for the company to finalise data cleaning activities.

Patients enrolled in Opthea’s double-masked Phase 2b trial received intravitreal injections of OPT302 on a monthly basis for 6 months.

Of the 366 patients randomised in the trial, 348, that's 95.1 per cent of patients completed the week 24 visit.

Shares in Opthea (ASX:OPT) closed -2.16 per cent lower at $0.68 yesterday.
 

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?